Altamira Therapeutics Ltd
NASDAQ:CYTO
Net Margin
Altamira Therapeutics Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | CH |
| Market Cap | 3.3m USD |
| Net Margin | N/A |
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Net Margin |
-79%
|
| Country | US |
| Market Cap | 742.2B USD |
| Net Margin |
17%
|
| Country | DK |
| Market Cap | 4T DKK |
| Net Margin |
37%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Net Margin |
-4%
|
| Country | US |
| Market Cap | 366.6B USD |
| Net Margin |
45%
|
| Country | US |
| Market Cap | 333.1B USD |
| Net Margin |
4%
|
| Country | UK |
| Market Cap | 187.5B GBP |
| Net Margin |
13%
|
| Country | CH |
| Market Cap | 189B CHF |
| Net Margin |
20%
|
| Country | CH |
| Market Cap | 182.7B CHF |
| Net Margin |
30%
|
| Country | US |
| Market Cap | 162.6B USD |
| Net Margin |
-1%
|
Profitability Report
View the profitability report to see the full profitability analysis for Altamira Therapeutics Ltd.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Altamira Therapeutics Ltd's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet
